Search

Your search keyword '"Graf, Solomon A."' showing total 186 results
Start Over Author "Graf, Solomon A."
186 results on '"Graf, Solomon A."'

7. EBV‐Positive Classic Hodgkin Lymphoma and Primary Nodal T‐Cell/NK‐Cell Lymphoma Arising in the Background of Follicular Lymphoma.

Author

Raychaudhuri, Suravi, Dong, Zhao Ming, Knowles, Scott, Graf, Solomon, and Piccaluga, Pier Paolo

Subjects
HODGKIN'S disease, FOLLICULAR lymphoma, HEMOPHAGOCYTIC lymphohistiocytosis, LYMPHOMAS, LYMPH nodes
Abstract

EBV‐positive primary nodal T‐cell/NK cell lymphoma (TNKL) is a rare diagnosis with a poor prognosis. No relationship with follicular lymphoma (FL), classic Hodgkin lymphoma (cHL), or other non‐Hodgkin lymphomas is established. We describe a case of Epstein–Barr virus (EBV)‐positive cHL and EBV‐positive primary nodal TNKL in the background of an antecedent FL, with all 3 subtypes identified in a single lymph node biopsy from an immunocompetent patient. Intensive frontline therapy achieved only a temporary response, with subsequent rapid progression associated with hemophagocytic lymphohistiocytosis (HLH). We discuss the relationship of the three lymphoma subtypes and the potential roles of EBV and immune dysregulation as contributing factors to this previously undescribed composite lymphoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Author

Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Fromm, Jonathan R., Wu, David, Holmberg, Leona A., Till, Brian G., Chauncey, Thomas R., Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian J., Libby, Edward N., III, Bensinger, William I., Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.

Published
2016
Full Text
View/download PDF

13. Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Author

Graf, Solomon A., primary, Lynch, Ryan C., additional, Ujjani, Chaitra S., additional, Gooley, Ted A, additional, Coffey, David G., additional, Cowan, Andrew J., additional, Smith, Stephen D., additional, Shadman, Mazyar, additional, Warren, Edus H., additional, Libby, Edward, additional, Godwin, Colin D., additional, Greninger, Alexander L, additional, Fromm, Jonathan R., additional, and Gopal, Ajay K, additional

Published
2021
Full Text
View/download PDF

17. Tagging and tracking individual networks within a complex mitochondrial web with photoactivatable GFP

Author

Twig, Gilad, Graf, Solomon A., Wikstrom, Jakob D., Mohamed, Hibo, Haigh, Sarah E., Elorza, Alvaro, Deutsch, Motti, Zurgil, Naomi, Reynolds, Nicole, and Shirihai, Orian S.

Subjects
Mitochondria -- Research, Proteins -- Research, Apoptosis -- Research, Biological sciences
Abstract

Assembly of mitochondria into networks supports fuel metabolism and calcium transport and is involved in the cellular response to apoptotic stimuli. A mitochondrial network is defined as a continuous matrix lumen whose boundaries limit molecular diffusion. Observation of individual networks has proven challenging in live cells that possess dense populations of mitochondria. Investigation into the electrical and morphological properties of mitochondrial networks has therefore not yielded consistent conclusions. In this study we used matrix-targeted, photoactivatable green fluorescent protein to tag single mitochondrial networks. This approach, coupled with real-time monitoring of mitochondrial membrane potential, permitted the examination of matrix lumen continuity and fusion and fission events over time. We found that adjacent and intertwined mitochondrial structures often represent a collection of distinct networks. We additionally found that all areas of a single network are invariably equipotential, suggesting that a heterogeneous pattern of membrane potential within a cell's mitochondria represents differences between discrete networks. Interestingly, fission events frequently occurred without any gross morphological changes and particularly without fragmentation. These events, which are invisible tinder standard confocal microscopy, redefine the mitochondrial network boundaries and result in electrically disconnected daughter units. membrane potential; fusion; fission; heterogeneity; green fluorescent protein; tetramethylrhodamine ethyl ester perchlorate

Published
2006

18. Synergistic amplification of [beta]-amyloid- and interferon-[gamma]-induced microglial neurotoxic response by the senile plaque component chromogranin A

Author

Twig, Gilad, Graf, Solomon A., Messerli, Mark A., Smith, Peter J.S., Yoo, Seung H., and Shirihai, Orian S.

Subjects
Alzheimer's disease -- Research, Monoamine oxidase -- Research, Biological sciences
Abstract

Activation of the microglial neurotoxic response by components of the senile plaque plays a critical role in the pathophysiology of Alzheimer's disease (AD). Microglia induce neurodegeneration primarily by secreting nitric oxide (NO), tumor necrosis factor-[alpha] (TNF[alpha]), and hydrogen peroxide. Central to the activation of microglia is the membrane receptor CD40, which is the target of costimulators such as interferon-[gamma] (IFN[gamma]). Chromogranin A (CGA) is a recently identified endogenous component of the neurodegenerative plaques of AD and Parkinson's disease. CGA stimulates microglial secretion of NO and TNF[alpha], resulting in both neuronal and microglial apoptosis. Using electrochemical recording from primary rat microglial cells in culture, we have shown in the present study that CGA alone induces a fast-initiating oxidative burst in microglia. We compared the potency of CGA with that of [beta]-amyloid ([beta]A) under identical conditions and found that CGA induces 5-7 times greater NO and TNF[gamma] secretion. Coapplication of CGA with [beta]A or with IFN[gamma] resulted in a synergistic effect on NO and TNF[alpha] secretion. CD40 expression was induced by CGA and was further increased when [beta]A or IFN[gamma] was added in combination. Tyrphostin A1 (TyrA1), which inhibits the CD40 cascade, exerted a dose-dependent inhibition of the CGA effect alone and in combination with IFN[gamma] and [beta]A. Furthermore, CGA-induced mitochondrial depolarization, which precedes microglial apoptosis, was fully blocked in the presence of TyrA1. Our results demonstrate the involvement of CGA with other components of the senile plaque and raise the possibility that a narrowly acting agent such as TyrA1 attenuates plaque formation. Alzheimer's disease; oxidative burst; apoptosis; nitric oxide; tyrphostin-A1

Published
2005

20. Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Author

Graf, Solomon A., primary, Lynch, Ryan C., additional, Gooley, Ted A, additional, Ujjani, Chaitra S., additional, Wilcox, Peter, additional, Wilcox, Sabrina, additional, Coffey, David G., additional, Cowan, Andrew J., additional, Smith, Stephen D., additional, Shadman, Mazyar, additional, Warren, Edus H., additional, Libby, Edward, additional, Godwin, Colin D., additional, Cassaday, Ryan D., additional, Fromm, Jonathan R., additional, and Gopal, Ajay K., additional

Published
2020
Full Text
View/download PDF

21. Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Author

Shadman, Mazyar, primary, Yeung, Cecilia, additional, Redman, Mary W, additional, Lee, Sang Yun, additional, Lee, Dong Hoon, additional, Ramachandran, Ajeetha, additional, Ra, Susan, additional, Marzbani, Edmond A, additional, Graf, Solomon A., additional, Warren, Edus H., additional, Gopal, Ajay K., additional, Chapuis, Aude G., additional, Bar, Merav, additional, Green, Damian J., additional, Gauthier, Jordan, additional, Cassaday, Ryan D., additional, Kiem, Hans-Peter, additional, Turtle, Cameron J., additional, Maloney, David G., additional, and Till, Brian G., additional

Published
2020
Full Text
View/download PDF

25. Androgens and estrogens predict sexual function after autologous hematopoietic stem cell transplant in men.

Author

Anderson, Lindsey J., Migula, Dorota, Abay, Rebecca, Crabtree, Stephanie, Graf, Solomon A., Matsumoto, Alvin M., Chauncey, Thomas R., and Garcia, Jose M.

Subjects
HEMATOPOIETIC stem cells, STEM cell transplantation, ESTROGEN, ANDROGENS, HEMATOPOIETIC stem cell transplantation
Abstract

Background: Autologous hematopoietic stem cell transplantation (AHSCT) is associated with sexual dysfunction and hypogonadism. Androgens are associated with sexual function in healthy men, but the role of estrogens is less well‐known, and the association of these sex steroids with sexual function during AHSCT has not been characterized. Objectives: The purpose of this study was to determine the predictive value of sex hormones before and acutely after AHSCT on sexual function recovery. Materials and methods: We examined sex hormones and self‐reported sexual function before (PRE) and 1‐month post‐AHSCT (MONTH1; n = 19), and sexual function again 1‐year post‐AHSCT in men (YEAR1; n = 15). Results: Sexual function decreased from PRE to MONTH1 (p ≤ 0.05) with no differences between PRE and YEAR1. Erectile dysfunction was prevalent at PRE (68.4%) and increased at MONTH1 (100%; p ≤ 0.05) but was not different between PRE and YEAR1 (60.0%). From PRE to MONTH1, total testosterone (TT), dihydrotestosterone (DHT), follicle‐stimulating hormone, and sex‐hormone‐binding globulin (SHBG) increased (p ≤ 0.02) while estradiol (p ≤ 0.026) and estrone decreased (p ≤ 0.001). MONTH1 TT and DHT were associated with sexual function at MONTH1, while PRE SHBG, MONTH1 estradiol, and change in estrone predicted sexual function at YEAR1. Discussion: Sexual dysfunction is very prevalent prior to AHSCT and is transiently and severely worsened acutely after. AHSCT induces acute decreases in total and free estrogens, with SHBG increases leading to increases in total androgens, without changes in free androgens. Conclusion: Androgens and estrogens are both adversely affected by AHSCT but may predict sexual dysfunction in this population. This supports the premise that estrogen impacts sexual function independent from androgens and that steroid hormones are associated with acute changes in sexual function in this setting. Larger, controlled trials with long‐term sex hormone assessment will need to confirm the association between early changes in estrogens and long‐term sexual function recovery. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Author

Graf, Solomon A., primary, Cassaday, Ryan D., additional, Morris, Karolyn K., additional, Behnia, Sanaz, additional, Wu, Qian Vicky, additional, Voutsinas, Jenna M., additional, Lynch, Ryan C., additional, Krakow, Elizabeth, additional, Rasmussen, Heather A., additional, Chauncey, Thomas R., additional, Kanan, Sandra, additional, Soma, Lorinda A., additional, Smith, Stephen D., additional, and Gopal, Ajay K., additional

Published
2019
Full Text
View/download PDF

32. A Window Study of Ixazomib in Untreated B-NHL

Author

Graf, Solomon A., primary, Lynch, Ryan C., additional, Ujjani, Chaitra S., additional, Coffey, David G., additional, Cowan, Andrew J., additional, Smith, Stephen D., additional, Shadman, Mazyar, additional, Warren, Edus H., additional, Libby, Edward N., additional, Godwin, Colin D., additional, Cassaday, Ryan D., additional, Gooley, Ted A, additional, Fromm, Jonathan R., additional, and Gopal, Ajay K., additional

Published
2019
Full Text
View/download PDF

34. Assessing Cachexia Acutely after Autologous Stem Cell Transplant

Author

Anderson, Lindsey J., primary, Yin, Chelsea, additional, Burciaga, Raul, additional, Lee, Jonathan, additional, Crabtree, Stephanie, additional, Migula, Dorota, additional, Geiss-Wessel, Kelsey, additional, Liu, Haiming M., additional, Graf, Solomon A., additional, Chauncey, Thomas R., additional, and Garcia, Jose M., additional

Published
2019
Full Text
View/download PDF

39. Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy

Author

Graf,Solomon and Garcia,Jose

Subjects
Drug Design, Development and Therapy
Abstract

Solomon A Graf,1–3 Jose M Garcia4,5 1Veterans Affairs Puget Sound Health Care System, 2Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, 3Clinical Research Division, Fred Hutchinson Cancer Research Center, 4Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, 5Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington School of Medicine, Seattle, WA, USA Abstract: Cancer anorexia–cachexia syndrome (CACS) is a complex and largely untreatable paraneoplastic complication common in advanced cancer. It is associated with profoundly deleterious effects on quality of life and survival. Since its discovery over a decade ago, anamorelin hydrochloride (anamorelin), a mimetic of the growth hormone secretagogue ghrelin, has shown considerable promise in ameliorating components of CACS when administered to patients with advanced cancer, including loss of lean body mass and reversal of anorexia. This review summarizes the development of anamorelin and its safety and efficacy in clinical investigations. The potential future role of anamorelin in treating CACS is also discussed. Keywords: anamorelin, cachexia, anorexia, ghrelin, non-small cell lung cancer

Published
2017

40. Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Author

Graf, Solomon A., primary, Cassaday, Ryan D., additional, Morris, Karolyn K., additional, Rasmussen, Heather A., additional, Becker, Pamela S., additional, Chauncey, Thomas R., additional, Kanan, Sandra, additional, Soma, Lorinda A., additional, Smith, Stephen D., additional, and Gopal, Ajay K., additional

Published
2018
Full Text
View/download PDF

41. Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Author

Graf, Solomon A., primary, Lynch, Ryan C., additional, Coffey, David G., additional, Shadman, Mazyar, additional, Kanan, Sandra, additional, Libby, Edward N., additional, Warren, Edus H., additional, Godwin, Colin, additional, Gooley, Ted, additional, Fromm, Jonathan R., additional, and Gopal, Ajay K., additional

Published
2018
Full Text
View/download PDF

45. Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission

Author

Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Fromm, Jonathan R., Wu, David, Holmberg, Leona A., Till, Brian G., Chauncey, Thomas R., Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian, Libby, Edward N., Bensinger, William I., Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.

Subjects
Adult, Male, Neoplasm, Residual, Transplantation Conditioning, Remission Induction, Hematopoietic Stem Cell Transplantation, Lymphoma, Mantle-Cell, Middle Aged, Survival Analysis, Transplantation, Autologous, Article, body regions, hemic and lymphatic diseases, Humans, Female, Aged
Abstract

Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 2.38 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR.

Published
2015

46. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

Author

Onishi, Maika, Graf, Solomon A., Holmberg, Leona, Behnia, Sanaz, Shustov, Andrei R., Schiavo, Karen, Philip, Mary, Libby, Edward N., Cassaday, Ryan D., Pagel, John M., Roden, Jennifer E., Maloney, David G., Green, Damian J., Till, Brian G., Press, Oliver W., Smith, Stephen D., and Gopal, Ajay K.

Subjects
Adult, Brentuximab Vedotin, Male, Immunoconjugates, Adolescent, Middle Aged, Prognosis, Hodgkin Disease, Article, Young Adult, Treatment Outcome, Fluorodeoxyglucose F18, Positron-Emission Tomography, Humans, Female, Platinum
Abstract

Normalization of fluorodeoxyglucose positron emission tomography (FDG PET) imaging prior to high-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes in relapsed and refractory (RR) Hodgkin lymphoma (HL), but many patients refractory to platinum-based salvage regimens are unable to achieve this goal. We therefore investigated whether brentuximab vedotin (BV) could normalize FDG PET in platinum-refractory HL prior to ASCT. Fifteen consecutive patients with RR HL and FDG PET positive disease after platinum-based salvage therapy were treated with a median of 4 cycles of BV. Normalization of FDG PET (Deauville ≤2) occurred in 8/15 (53%) patients but was only observed in patients that had achieved partial remission or stable disease after platinum-based salvage therapy. All patients eventually proceeded to ASCT, regardless of FDG PET status. Our data suggest that BV can normalize FDG PET in a subset of patients with platinum-refractory HL prior to ASCT.

Published
2014

48. Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Author

Cowan, Andrew J., primary, Stevenson, Philip A., additional, Cassaday, Ryan D., additional, Graf, Solomon A., additional, Holmberg, Leona, additional, Fromm, Jonathan R., additional, Till, Brian G., additional, Wu, David, additional, Chauncey, Thomas, additional, Smith, Stephen D., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Shustov, Andrei R., additional, Green, Damian J., additional, Libby, Edward N., additional, Bensinger, William, additional, Shadman, Mazyar, additional, Maloney, David G., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2015
Full Text
View/download PDF

49. Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Author

Orozco, Johnnie J., Gooley, Ted, Rajendran, Joseph G., Fisher, Darrell R., Deeg, H. Joachim, Storb, Rainer F., Mawad, Raya, Shadman, Mazyar, Cassaday, Ryan D., Green, Damian J., Gopal, Ajay K., Till, Brian G., Graf, Solomon, Haaf, Robyn, Lundberg, Sally J., O'Donnell, Paul, Press, Oliver W., Appelbaum, Frederick R., Pagel, John M., and Sandmaier, Brenda M.

Published
2017
Full Text
View/download PDF

50. Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Author

Fengting Yan, Gopal, Ajay K., and Graf, Solomon A.

Subjects
MANTLE cell lymphoma, STEM cell transplantation, TOXICITY testing, DISEASE remission, CANCER chemotherapy, THERAPEUTICS
Abstract

The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results